TempraMed Technologies Ltd. Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), is pleased to announce that, further to its September 23, 2026 and September 28, 2026 news releases, it has closed its non-brokered private placement (the "Offering") of unsecured convertible debentures of the Company (each, a "Convertible Debenture") and units (each, a "Unit"). The Company issued $600,000 of principal amount of Convertible Debentures and 1,155,880...
2026-09-30 6:00 PM EDT
TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Toronto, Ontario--(New
2026-09-29 3:05 AM EDT
TempraMed Announces Upsize to Offering
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering will include up to C$600,000 in unsecured convertible debentures (each, a "Debenture") and up to C$1,000,000 in units (each, a "Unit") for aggregate gross proceeds of up to...
2026-09-28 5:49 PM EDT
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets. The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™. TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026. Initial extended-territory framework contemplates minimum units across the added countries, with additional...
2026-09-24 2:55 AM EDT
TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health...
2026-09-23 3:05 AM EDT
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide an interim sales update regarding its recent commercial performance. The Company reports that July 2026 sales reached approximately US$522,000, representing the highest monthly sales level in TempraMed's history....
2026-09-18 4:45 PM EDT
TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece
Highlights: LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum unit commitment will be negotiated and established in the definitive distribution agreement. CPO Greece brings an established...
2026-09-01 6:45 AM EDT
TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap
Highlights Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order. Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain. TempraMed believes the private-label structure can improve in-store commitment, pharmacist engagement and consumer promotion...
2026-08-25 7:00 AM EDT
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year under the same terms. For more...
2026-08-20 7:00 AM EDT
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed is pleased to announce that it has entered into a definitive exclusive distribution agreement (the
2026-08-18 7:00 AM EDT
TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a strategic partnership with Stealth Health (stealth.health), a leading telemedicine platform for longevity and precision wellness in North America. The agreement integrates TempraMed's VIVI product portfolio into...
2026-08-04 7:00 AM EDT
TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DTC eligible, significantly enhancing the accessibility and efficiency of trading for U.S. investors. TempraMed common shares trade on the OTCQB under the symbol...
2026-07-30 7:00 AM EDT
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY
2026-07-09 7:00 AM EDT
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
Toronto, Ontario--(Newsfile Corp. - July 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY)
2026-07-06 7:00 AM EDT
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the largest...
2026-06-30 3:05 AM EDT
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company ("Rawafed"), a leading healthcare distribution company with broad reach across pharmacy networks and healthcare...
2026-06-26 4:10 PM EDT
TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI)
2026-06-04 7:00 AM EDT
TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed a medical technology innovator transforming how temperature sensitive medications are stored and managed, is pleased to announce that TempraMed is featured on the Dr. Phil Show in a national broadcast episode focused on the real and often...
2026-05-22 11:57 AM EDT
TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transform
2026-05-14 3:00 AM EDT
TempraMed Announces Continuance into Ontario
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the Business Corporations Act...
2026-04-29 4:30 PM EDT